ADMA Biologics Faces Legal Scrutiny Over Alleged Revenue Inflation Tactics

New York, Thursday, 7 May 2026.
Following a 29% stock crash, ADMA Biologics is under investigation for allegedly inflating its 2025 revenue growth to hide deteriorating demand for its medical products.